Dataset Information

Haplotype analysis of GSK-3? gene polymorphisms in bipolar disorder lithium responders and nonresponders.

ABSTRACT: The GSK-3? gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074). Haplotype 1 (T-A) was associated with a higher lithium response (haplotype-specific P=0.03477), whereas haplotype 2 (C-A) was associated with a lower lithium response (haplotype-specific P=0.03443).The pairwise D' and r values between the 2 SNPs in this study were 1.0 and 0.097, respectively. The 2 SNPs showed weak linkage disequilibrium with each other.

SUBMITTER: Iwahashi K

PROVIDER: S-EPMC4206383 | biostudies-literature | 2014 Jul-Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.

Iwahashi Kazuhiko K Nishizawa Daisuke D Narita Shin S Numajiri Maki M Murayama Ohoshi O Yoshihara Eiji E Onozawa Yuuya Y Nagahori Kenta K Fukamauchi Fumihiko F Ikeda Kazutaka K Ishigooka Jun J

Clinical neuropharmacology 20140701 4

The GSK-3β gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium no ...[more]

PMID: 24992082

Similar Datasets

Project description:BackgroundThe treatment of bipolar disorder (BD) remains a challenge due to the complexity of the disease. Current guidelines represent an effort to assist clinicians in routine practice but have several limitations, particularly concerning long-term treatment. The ARIQUELI (efficacy and tolerability of the combination of lithium or aripiprazole in young bipolar non or partial responders to quetiapine monotherapy) study aims to evaluate two different augmentation strategies for quetiapine nonresponders or partial responders in acute and maintenance phases of BD treatment.Methods/designThe ARIQUELI study is a single-site, parallel-group, randomized, outcome assessor-blinded trial. BD I patients according to the DSM-IV-TR, in depressive, manic/hypomanic or mixed episode, aged 18 to 40 years, are eligible. After diagnostic assessments, patients initiated treatment in phase I with quetiapine. Nonresponders or partial responders after 8 weeks are allocated into one of two groups, potentiated with either lithium (0.5 to 0.8 mEq/l) or aripiprazole (10 or 15 mg). Patients will be followed up for 8 weeks in phase I (acute treatment), 6 months in phase II (continuation treatment) and 12 months in phase III (maintenance treatment). Outcome assessors are blinded to the treatment. The primary outcome is the evaluation of changes in mean scores on the CGI-BP-M between baseline and the endpoint at the end of each study phase.DiscussionThe ARIQUELI study is currently in progress, with patients undergoing acute treatment (phase I), potentiation (phase II) and maintenance (phase III). The study will be extended until January 2015. Trials comparing lithium and aripiprazole with potentiate treatment in young BD I nonresponders to quetiapine in monotherapy can provide relevant information on the safety of these drugs in clinical practice. Long-term treatment is an issue of great importance and should be evaluated further through more in-depth studies given that BD is a chronic disease.Trial registrationClinicalTrials.gov identifier: NCT01710163.

Dataset Information

Haplotype analysis of GSK-3? gene polymorphisms in bipolar disorder lithium responders and nonresponders.

Publications

Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets